[1]许欢,陈竹,陈华,等.基于网络药理学及分子对接技术探讨运脾泻肺化痰汤治疗支气管哮喘的作用机制[J].西部中医药,2025,38(01):80-88.[doi:10.12174/j.issn.2096-9600.2025.01.16]
　XU Huan,CHEN Zhu,CHEN Hua,et al.Effects of Spleen-invigorating Lung-purging Phlegm-resolving Decoction on Bronchial Asthma Based on Network Pharmacology and Molecular Docking[J].Western Journal of Traditional Chinese Medicine,2025,38(01):80-88.[doi:10.12174/j.issn.2096-9600.2025.01.16]
点击复制

基于网络药理学及分子对接技术探讨运脾泻肺化痰汤治疗支气管哮喘的作用机制()
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
38
期数:
2025年01期
页码:
80-88
栏目:
二次研究
出版日期:
2025-01-15

文章信息/Info

Title:
Effects of Spleen-invigorating Lung-purging Phlegm-resolving Decoction on Bronchial Asthma Based on Network Pharmacology and Molecular Docking
作者:
许欢1, 陈竹2, 陈华2, 陈娜2, 张芷瑞2
1.抚州市中医医院，江西 抚州 344001
2.贵州中医药大学，贵州 贵阳 550001
Author(s):
XU Huan1, CHEN Zhu2, CHEN Hua2, CHEN Na2, ZHANG Zhirui2
1.Fuzhou Hospital of Traditional Chinese Medicine, Fuzhou 344001, China
2.Guizhou University of Traditional Chinese Medicine, Guiyang 550001, China
关键词:
支气管哮喘; 运脾泻肺化痰汤; 网络药理学; 分子对接; 信号通路
Keywords:
bronchial asthma; spleen-invigorating lung-purging phlegm-resolving decoction; network pharmacology; molecular docking; signaling pathway
分类号:
R256.1
DOI:
10.12174/j.issn.2096-9600.2025.01.16
文献标志码:
A
摘要:
目的运用网络药理学和分子对接技术分析运脾泻肺化痰汤治疗支气管哮喘（简称哮喘）的作用机制。 方法通过中药系统药理学数据库与分析平台（traditional Chinese medicine systems pharmacology database and analysis platform，TCMSP）、Swiss Target Prediction数据库，检索运脾泻肺化痰汤各中药的有效活性成分及潜在靶点。通过人类基因数据库（the human gene database，GeneCards）、在线人类孟德尔遗传数据库（online mendelian inheritance in man，OMIM）、Drugbank、药物靶标数据库（therapeutic targetdatabase，TTD）、PharmGKB数据库检索“Bronchial asthma”和“Bronchial asthma in children”关键词，获得哮喘的相关靶基因，并与药物有效成分的靶点相映射得到共同靶点。利用Cytoscape 3.8.2构建运脾泻肺化痰汤-活性有效成分-作用靶点-生物学功能网络图，借助STRING数据库构建蛋白互作网络（protein-protein interactions，PPI）。通过Metascape数据库对靶点进行京都基因与基因组百科全书（kyoto encyclopedia of genes and genomes，KEGG）通路富集分析。 结果运脾泻肺化痰汤与哮喘相关基因取交集后得到288个共同靶点。通过STRING数据库分析得出288个靶点可以发生相互作用，产生了1803条代表蛋白之间相互作用的边，平均自由度为12.5，平均介数为＜1.0e-16。推测出运脾泻肺化痰汤治疗哮喘的核心靶点是STAT3、MAPK1、MAPK3、SRC。KEGG通路富集分析结果表明显著富集的通路有176条，其中PI3K/Akt、MAPK、Th17/IL17、TNF、JAK/STAT信号通路等11条可能是运脾泻肺化痰汤治疗哮喘的核心信号通路。分子对接结果表明，运脾泻肺化痰汤中的活性成分与关键靶点具有较高的结合能力。 结论运脾泻肺化痰汤最有可能通过调控PI3K/Akt信号通路治疗哮喘。
Abstract:
ObjectiveTo analyze the mechanism of spleen-invigorating lung-purging phlegm-resolving decoction (Yunpi Xiefei Huatan Tang) in the treatment of bronchial asthma based on network pharmacology and molecular docking technology. MethodsThe active ingredients of different herbs in the decoction and the potential targets were searched from TCMSP and Swiss Target Prediction database. "Bronchial asthma" and "bronchial asthma in children" as the keywords were retrieved from GeneCards, OMIM, TTD and PharmGKB database to obtain the related target genes for asthma, and map them to the targets of the active ingredients of the drug to obtain the common targets. Cytoscape 3.8.2 was applied to construct the network of spleen-invigorating lung-purging phlegm-resolving decoction-active ingredients-the targets of action-biological function, and to build PPI via String database. KEGG pathway enrichment analysis of the targets was performed via Metascape database. ResultsAll 288 common targets were obtained from the intersection of the decoction with asthma-related genes by analysis. The analysis of the STRING database yielded 288 targets that could interact, generating 1,803 edges representing interactions between proteins with an average degree of freedom of 12.5 and an average median of <1.0e-16. It was concluded that the core targets for the treatment of asthma with the decoction contained STAT3, MAPK1, MAPK3 and SRC. The results of KEGG pathway enrichment analysis demonstrated that 176 pathways were significantly enriched, among them, 11 pathways including PI3K/Akt signaling pathway, MAPK signaling pathway Th17/IL17, TNF signaling pathway, JAK/STAT signaling pathway and others might be the core pathways for the treatment of asthma with the decoction. The results of molecular docking showed that the active ingredients of the decoction presented higher binding ability with the key targets. ConclusionThe decoction could treat asthma possibly through regulating PI3K/Akt signaling pathway.

相似文献/References:

[1]向建华,毛良平,韩鹏凯,等.沙美特罗替卡松联合金水宝胶囊治疗中度非急性发作期支气管哮喘100例临床观察*[J].西部中医药,2013,26(05):97.
　XIANG Jianhua,MAO Liangping,HAN Pengkai,et al.Observation on Salmeterol Fluticasone Combined with JinShuiBao Capsule for 100 Cases of Moderate Bronchial Asthma during the Period of Non Acute Attack[J].Western Journal of Traditional Chinese Medicine,2013,26(01):97.
[2]玛丽亚,孙学健,严兴海.新疆昌吉地区238例支气管哮喘发作期患者中医证型分布[J].西部中医药,2013,26(12):63.
　MA Liya,SUN Xuejian,YAN Xinghai.TCM Patterns Distribution of 238 Cases of Bronchial Asthma at Exacerbation Stage in Changji of XinJiang[J].Western Journal of Traditional Chinese Medicine,2013,26(01):63.
[3]王盛强.中西医结合治疗发作期支气管哮喘48例[J].西部中医药,2014,27(02):110.
　WANG Shengqiang.Treating 48 Cases of Bronchial Asthma at Attack Stage by Integrative Medicine[J].Western Journal of Traditional Chinese Medicine,2014,27(01):110.
[4]吴大斌.益气固本汤合俞募配穴敷贴治疗支气管哮喘45例[J].西部中医药,2014,27(10):127.
[5]张晔敏.川芎平喘合剂治疗慢性持续期支气管哮喘74例[J].西部中医药,2014,27(12):64.
[6]祝伟,田浩.川芎嗪联合小剂量雷公藤治疗儿童哮喘急性发作期患儿38例[J].西部中医药,2015,28(02):102.
[7]贾红光,罗永伟,陈超,等.对支气管哮喘患者电话随访式健康教育的效果评价[J].西部中医药,2015,28(12):115.
[8]张坤,秦慧娟,陈桂花△.基于中医体质的健康管理对支气管哮喘患者远期疗效的影响[J].西部中医药,2019,32(04):123.
　ZHANG Kun,QIN Huijuan,CHEN Guihua.Effects of Health Management on Long-term Outcomes of the Patients with Bronchial Asthma Based on TCM Constitution[J].Western Journal of Traditional Chinese Medicine,2019,32(01):123.
[9]李亚,李春梅,陈茜.加味小青龙汤联合沙美特罗替卡松治疗支气管哮喘疗效观察[J].西部中医药,2020,33(04):103.[doi:10.12174/j.issn.1004-6852.2020.04.31]
　LI Ya,LI Chunmei,CHEN Qian.Clinical Observation on Modified XiaoQinglong Tang Joined with Salmeterol Fluticasone in Treating Bronchial Asthma[J].Western Journal of Traditional Chinese Medicine,2020,33(01):103.[doi:10.12174/j.issn.1004-6852.2020.04.31]
[10]李素娟 彭万胜 陈开泉.基于行为转变理论对支气管哮喘患儿开展延续性护理的效果观察[J].西部中医药,2020,33(S1):94.
　Li Sujuan Peng Wansheng Chen Kaiquan.Observation on the Effects of Carrying out Continuous Care for Children with Bronchial Asthma Based on Trans-theoretical Model[J].Western Journal of Traditional Chinese Medicine,2020,33(01):94.

备注/Memo

备注/Memo:
许欢（1991—），女，硕士学位，主治医师。研究方向：中医药防治小儿肺脾系统疾病。国家自然科学基金（81860868）；贵州省中医儿科诊疗中心建设项目（黔中医药函〔2021〕58号）。
更新日期/Last Update: 2025-01-15